Strattera (Atomoxetine) and Sperm Quality
Based on emerging preclinical evidence, atomoxetine (Strattera) appears to impair human sperm quality and function, though the FDA label does not report fertility impairment in animal studies at therapeutic doses.
Key Evidence from FDA Drug Label
The FDA label for Strattera states that atomoxetine did not impair fertility in rats at doses up to 57 mg/kg/day (approximately 6 times the maximum human dose) 1. However, this animal data may not fully capture effects on human sperm function, as discussed below.
The label does document sexual side effects in adult males, including testicular pain as a postmarketing adverse event 1, and common treatment-emergent adverse reactions including erectile dysfunction (8.0% vs 1.9% placebo), ejaculation disorder (2.8% vs 1.1% placebo), and urinary hesitation (6.9% vs 2.4% placebo) 1. These sexual side effects occur early (within 2-3 weeks) and may take 3-8 weeks to resolve after onset 2.
Recent Preclinical Evidence Raises Concerns
A 2026 in vitro study provides the most direct evidence that atomoxetine compromises human sperm function 3. This study demonstrated:
- Concentration- and time-dependent inhibition of sperm motility at clinically relevant concentrations (1-500 μM)
- At 50 μM, progressive motility was reduced by nearly 50% (27.8% vs 53.0% in controls) without causing cell death, indicating specific functional impairment
- Disruption of calcium homeostasis, specifically abolishing progesterone-induced calcium influx
- Impairment of PKC-dependent calcium signaling, which is critical for sperm capacitation and the acrosome reaction
- Defects in capacitation and acrosome reaction that could impair fertilization capacity
A companion 2026 study on Leydig cells found that atomoxetine reduced testosterone biosynthesis, increased apoptosis, caused DNA damage, and altered oxidative stress markers in testosterone-producing cells 4. This suggests potential effects beyond direct sperm toxicity.
Clinical Context and Recommendations
For Men Currently Taking Strattera Who Are Trying to Conceive:
Discuss with the prescribing physician whether atomoxetine can be discontinued or switched to an alternative ADHD medication with less reproductive concern. The in vitro evidence suggests functional impairment at therapeutic concentrations, though clinical fertility outcomes in humans remain unstudied.
For Men Planning Future Fertility:
Consider baseline semen analysis before starting atomoxetine if fertility preservation is a concern. If sperm parameters decline during treatment, the effects appear to be mediated through reversible signaling disruption rather than permanent cellular damage 3.
Important Caveats:
- No human clinical studies have directly assessed fertility outcomes in men taking atomoxetine
- The in vitro findings 3 used concentrations that may be achieved with therapeutic dosing, but plasma levels don't necessarily reflect concentrations at the level of sperm
- The FDA animal studies 1 showed no fertility impairment, but these used different species and may not detect subtle sperm functional defects
- A 2020 review noted that data on non-SSRI medications (including atomoxetine as a norepinephrine reuptake inhibitor) are "sparse, varied and conflicting" 5
Monitoring Approach:
If continuing atomoxetine while attempting conception:
- Obtain semen analysis if pregnancy is not achieved after 6-12 months of trying
- Evaluate for the common sexual side effects (erectile dysfunction, ejaculatory dysfunction) that occur in 8-10% of adult males 1, 2
- Consider that sexual dysfunction may compound any direct effects on sperm quality
The preclinical evidence suggests caution, particularly given that the mechanism involves disruption of critical sperm signaling pathways rather than just cytotoxicity 3. However, the absence of human clinical data means the true fertility risk remains uncertain. Shared decision-making with consideration of ADHD treatment alternatives is warranted for men actively pursuing conception.